Feng Fang1 article listing Feng Fang in Nature Communications, indexed by Paperzzz from Crossref and OSF.Perioperative tislelizumab plus lenvatinib treatment for resectable hepatocellular carcinoma at high risk of recurrence: single-arm phase II trial Nature Communications